Search Results
Found 169 results for "Merck" across articles, medicines, trials, companies and the glossary
💊 MedicinesAll 161 →
Bavencio 20 mg/mL concentrate for solution for infusionAvelumab · Merck Europe B.V.
Bridion 100 mg/ml solution for injectionSugammadex · Merck Sharp & Dohme BV
Campral EC 333mg Gastro-resistant tabletsAcamprosate calcium · Merck Serono (Ireland) Limited
Cancidas 50 mg powder for concentrate for solution for infusionCaspofungin · Merck Sharp & Dohme BV
Cancidas 70 mg powder for concentrate for solution for infusionCaspofungin · Merck Sharp & Dohme BV
CAPVAXIVE solution for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (21-valent)Pneumococcal Polysaccharide Serotype 3 Conjugated to CRM197, Pneumococcal Polysaccharide Serotype 6A Conjugated to CRM197, Pneumococcal polysaccharide serotype 7F conjugated to CRM197, Pneumococcal polysaccharide serotype 8 conjugated to CRM197, Pneumococcal polysaccharide serotype 9N conjugated to CRM197 · Merck Sharp & Dohme BV,
🧬 Clinical trials in IrelandTracker →
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Can…Active · Merck Sharp & Dohme LLC
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembroli…Active · Merck Sharp & Dohme LLC
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Pa…Active · Merck Sharp & Dohme LLC
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintena…Recruiting · Merck Sharp & Dohme LLC
🏢 CompaniesDirectory →
Merck KGaAPharmaceutical · Darmstadt
Pharma & MedTech
Global Biopharma M&A Rebounds in 2026: AbbVie and Merck KGaA Lead Multi-Billion Dollar Acquisitions
Global pharmaceutical dealmaking has surged in 2026 as cash-rich majors AbbVie and Merck KGaA close multi-billion dollar acquisitions to restock pipelines ahead of late-decade patent cliffs.
Industry News
The 2026 Obesity Power Rankings: Which Pharma Giants Can Break the Lilly-Novo Duopoly?
With the obesity market projected to exceed $130 billion by 2034, we analyze the top 10 pharmaceutical companies vying for dominance. Explore our comprehensive Power Rankings assessing pipeline depth, clinical differentiation, and commercial infrastructure.
Industry News
A Biotech Buying Frenzy: Inside the H1 2026 Pharma M&A Surge
An in-depth analysis of the massive wave of pharmaceutical mergers and acquisitions in the first half of 2026, driven by patent cliffs, pipeline replenishment, and high-growth therapeutic areas.